This study was designed to compare the efficacy of angiogenic gene delivery by ultrasound-mediated (UM) destruction of intravenous carrier microbubbles to direct intramuscular (IM) injections.
Over the past 2 decades, there have been numerous clinical trials designed to promote new vessel growth by proangiogenic gene delivery in patients with refractory symptomatic coronary artery disease and peripheral arterial disease (1) . Whereas initial small open-labeled trials yielded promising results, subsequent larger double-blind, randomized, placebo-controlled, clinical trials have failed to show significant clinical benefits (2, 3) . The largely disappointing results of clinical trials of therapeutic angiogenesis may in part be explained by suboptimal delivery techniques (4, 5) , involving either intra-arterial or direct intramuscular injection.
Intra-arterial delivery of genes is largely ineffective and can result in systemic delivery (6) . Whereas intramuscular delivery is more effective (6) , this strategy remains limited by the inability to target specific cell types, the localized nature of transfection in proximity to injection sites, and the impracticality for repeated delivery into tissues such as the heart. The ability to noninvasively deliver genetic material to specific target tissues, such as the vascular endothelium, in a controlled manner would be an important step toward a safe and effective pro-angiogenic gene therapy.
Ultrasound-mediated (UM) destruction of intravenously administered deoxyribonucleic acid (DNA)-bearing carrier microbubbles during their microcirculatory transit has been used to amplify transfection of reporter plasmid DNA to skeletal (7) and cardiac muscle (8) . We have previously demonstrated that UM destruction of microbubbles bearing vascular endothelial growth factor-165 (VEGF 165 ) plasmid DNA results in enhanced transfection of the vascular endothelium and improved tissue perfusion in chronically ischemic skeletal muscle (9) . The aim of our present study was to compare gene delivery by ultrasonic destruction of intravenous VEGF 165 plasmid-bearing microbubbles to direct intramuscular (IM) injections, for therapeutic angiogenesis. The study was designed to test whether in the context of reduced limb blood flow, this vascular-based strategy would be superior to standard, but more invasive, direct IM injections, and whether the neovascularization response could be explained by the differences in the localization of gene transfection between delivery methods.
Methods
Microbubble and DNA preparation. Plasmid DNA was charge-coupled to cationic lipid microbubbles as previously described (7, 9) . For perfusion imaging, lipid-shelled decafluorobutane microbubbles were used. Microbubble concentrations were determined using a Coulter Multisizer IIe (Beckman Coulter, Fullerton, California). A bicistronic plasmid vector was constructed for the cotransfection of both enhanced green fluorescent protein (GFP) and human VEGF 165 (9) . Animal preparation. The study protocol was approved by the Animal Care and Use Committee at St. Michael's Hospital Research Centre, University of Toronto. Proximal hind-limb ischemia was produced in 99 Sprague-Dawley rats. Rats were anesthetized with intraperitoneal injection of ketamine hydrochloride (10 mg·kg Ϫ1 ) and xylazine (8 mg·kg Ϫ1 ). Under sterile conditions, the left common iliac artery and small proximal branches were exposed and ligated with 4-0 sutures. The incision was closed in layers and animals were recovered. Perfusion imaging. Contrast-enhanced ultrasound (CEU) imaging of the proximal hind-limb adductor muscles was performed as previously described (9) , to obtain perfusion data on microvascular blood volume (MBV), velocity, and microvascular blood flow (MBF) (9) . Gene delivery. For ultrasound-mediated (UM) gene delivery, cationic microbubbles (1 ϫ 10 9 ) coupled with 500 g of complementary DNA were infused intravenously during ultrasound transmission (Sonos 5500, Philips Healthcare, Andover, Massachusetts) at 1.3 MHz and a transmit power of 0.9 W, using a pulsing interval of 5 s (9). At these settings, peak negative acoustic pressure by needle hydrophone (PVDF-Z44, Specialty Engineering Associates, Sunnyvale, California) was calculated to be -2,100 kPa (assuming a tissue attenuation coefficient of 0.3 dB/cm/ MHz, at tissue depth of 1 cm). For IM gene delivery, 500 g of VEGF 165 /GFP plasmid DNA was injected directly into the ischemic hind-limb adductor muscle at 5 evenly spaced sites spanning the length and width of the proximal adductor muscle, using a 24-gauge needle. This resulted in a mean distance between injection sites of 5 mm. In a subset of animals (n ϭ 3), plasmid DNA was admixed with 10-m red fluorescent beads (100,000 beads/injection) before IM delivery, to allow for localization of transfection in relation to site of IM injection. Fluorescent microangiography. Immediately before sacrifice, the distal hind-limbs were flushed with heparinized saline via an abdominal aortic cannula. A 10% solution of fluorescent microspheres (0.2 m) (Sigma-Aldrich, St. Louis, Missouri) mixed with a 1% solution of low melting point agarose at 45 o C was injected at constant rate into the aortic cannula until seen on venous return. The animal was euthanized and placed in an ice bath to facilitate cooling and solidification of the casting agent. Hind-limb tissue was placed in 10% buffered formalin, sectioned (200 m) using a vibratome and visualized under confocal microscopy. A series of stacked images (4-m slices) were taken and the middle 25 slices (100-m total thickness) were projected to quantify the vessel density using automated software (IPTK analysis software, Reindeer Graphics Inc., Asheville, North Carolina) (9) . Immunohistochemistry. In vivo transfection efficacy and spatial localization was determined using immunohistochemistry. Explanted tissue was cryoembedded in optical cutting temperature compound (Sakura Finetek Japan, Tokyo, Japan) and stored at -80 o C. Cryo-blocks were sectioned (15-m thick) every 25 m and rehydrated in phosphate buffered saline (PBS), fixed in 2% paraformaldehyde (Sigma-Aldrich) in PBS, and washed with PBS. Cell surface antigens were identified using mouse antihuman CD31 (Alpha Diagnostics Inc., San Antonio, Texas), mouse antihuman Tie-2 (Clone Ab33, Upstate Biotechnology, Milford, Massachusetts), and mouse antihuman Alpha-actin (Sigma-Aldrich). The presence of antibody was confirmed by exposure to a phycoerythrin conjugated secondary antibody. TO-PRO-3 (Invitrogen, Burlington, Ontario, Canada) was used as a nuclear marker.
To better assess regional distribution, tissue was prepared and sectioned as described earlier and visualized under fluorescent microscopy for VEGF/GFP signal. Hind-limb skeletal muscle was divided into a 10 ϫ 10 grid (using 20ϫ high power fields) and every other field was scored for the presence of GFP signal (checkerboard grid with a total of 25 scored fields). Fields were deemed positive if clear GFP signal was detectable, and the number of positive fields (out of 25) was recorded.
To assess spatial localization in relation to site of IM injection, tissue was prepared and sectioned as described previously. Sections were visualized under low-magnification confocal microscopy and injection sites were identified by the presence of 10-m red fluorescent beads, which remained adjacent to the site of IM injection. Four adjacent low power fields were taken with the same confocal settings and recompiled to illustrate one contiguous image of GFP transfection in relation to the red fluorescent beads that mark the injection site. Reverse transcriptase-polymerase chain reaction. Semiquantitative real-time reverse transcriptase-polymerase chain reaction for exogenous VEGF 165 /GFP transcript was performed on hind-limb tissue, as previously described (9) . Briefly, tissue samples were harvested, flash frozen in liquid nitrogen, and stored at -80 o C until processing. Messenger ribonucleic acid (RNA) was isolated using the Aurum total RNA kit (Bio-Rad Laboratories, Mississauga, Ontario), which utilizes deoxyribonuclease to ensure no plasmid DNA contamination in the final product. Because, a bicistronic vector was used to deliver VEGF 165 /GFP, the following primers were used to assay for exogenous transgene expression: forward 5=-ACGTAAACGGCCACAAGTTC-3= and reverse 5=-AAGTCGTGCTGCTTCATGTG-3=. Experimental protocol. Contrast-enhanced ultrasound perfusion imaging of the ischemic and contralateral control hind-limb adductor muscles was performed 14 days after ligation. Gene delivery was then performed, according to assigned treatment groups: group 1-intramuscular injection of VEGF 165 /GFP plasmid (IM); group 2-ultrasound mediated VEGF 165 /GFP plasmid microbubble delivery (UM); and group 3-control group, no treatment (n ϭ 32 per group). Then, CEU imaging was performed at days 17, 21, and 28 and 8 weeks after ligation (n ϭ 8 per group). In 4 rats per group (days 28 and week 8), FMA was performed before sacrifice. An additional 3 rats underwent intramuscular injections of VEGF 165 /GFP plasmid mixed with red fluorescent beads and sacrificed 3 days later for determination of localization of GFP transfection in relation to the site of IM injections. Tissue for immunohistochemistry and reverse transcriptasepolymerase chain reaction was obtained from the remaining rats' ischemic and nonischemic hind limbs. Statistical methods. All data are expressed as mean Ϯ SD. Comparisons between groups at multiple stages were performed by 2-way analysis of variance; if significant, Bonferroni correction for multiple comparisons was applied when post-hoc analysis between different time points or between different groups at the same time point was performed (GraphPad Prism version 5.0a, GraphPad Software Inc., La Jolla, California). Statistical significance between 2 groups was determined by 2-tailed unpaired t tests. Differences were considered significant at p Ͻ 0.05 (2-sided).
Results
Comparison of transgene expression. Real-time reverse transcriptase-polymerase chain reaction data for exogenous VEGF 165 /GFP messenger RNA at various time points after delivery are shown in Figure 1 . Using specific primers, robust exogenous transgene expression (normalized to the contralateral nonischemic muscle) was detected in both IMand UM-treated ischemic muscles and was undetectable in control untreated animals. For both treatment groups, transfection was greatest at day 3 following delivery (day 17 after ligation), decreasing over time. The IM delivery resulted in significantly greater transfection compared with the UM delivery at all early time points, with transgene expression diminishing in both treatment groups by week 8 (Fig. 1) . Muscle perfusion and vascular density. At 2 weeks after iliac artery ligation, immediately before gene delivery, mean MBV and MBF in the ischemic leg was reduced to ϳ35% of the normal leg in all 3 groups (Fig. 2) . In the control group, there was no change in normalized MBV and MBF over time (Fig. 2) . With IM therapy, there was a significant increase in normalized MBV that began at day 17 following ligation, reaching a plateau at days 21 and 28, and waning by week 8. Whereas MBV increased early in IM-treated ischemic muscle, significant increases in MBF were not seen until day 28. In comparison, the improvement in perfusion with UM therapy was more delayed, with normalized MBV and MBF peaking at 28 days after ligation (14 days following gene delivery), and persisting to 8 weeks after ligation (Fig. 2) . When compared with IM therapy, UM therapy yielded a significantly greater improvement in normalized MBF than with IM therapy. This superior therapeutic effect of UM gene delivery was seen at 28 days after ligation and persisted out to week 8 (Fig. 2) . Fluorescent microangiography analysis revealed reduced vessel density in the control group's ischemic muscle 4 weeks after iliac artery ligation. Consistent with CEU perfusion data, at 14 days after gene delivery, there were increases in vessel density both in the IM and UM groups that mirrored changes in MBV. Whereas changes in MBF at day 28 were significantly greater for UM, as compared with IM, therapy, changes in both MBV and vessel density by FMA at day 28
between UM-and IM-treated animals were not significantly different (Figs. 2 and 3) . Localization of gene transfection. There was no discernable GFP signal detected in the ischemic muscle of the untreated control group. In comparison, a robust GFP signal was detected in both IM-and UM-treated groups by fluorescent confocal microscopy. Whereas IM gene delivery resulted in focal regions of bright GFP signal predominantly within regions adjacent to IM injection sites, UM-treated muscle showed a more diffuse signal with a significantly greater number of microscopic fields expressing GFP (Fig. 4) . For IM delivery, immunohistochemical staining revealed focal areas of colocalization of GFP predominantly within myocytes, with some signal from surrounding capillaries and interstitial cells of the ischemic adductor muscle (Fig. 5 ) and little to no signal from arterioles or venules. In UM-treated muscle, the GFP signal was predominantly associated with the vascular endothelium of small-and medium-sized arterioles within the ischemic adductor muscle, with signal also detected within capillaries and extending to surrounding myocytes (Fig. 5) .
Discussion
Currently, the most effective strategy for delivering angiogenic genes to induce clinically important therapeutic neovascularization within ischemic muscle is unknown. We have previously demonstrated the potential of UM destruction of VEGF 165 plasmid-bearing microbubbles for improving tissue perfusion in the setting of severe chronic hindlimb ischemia (9) . delivery of most of the genetic material directly into target tissue with minimal systemic effects, this method is invasive, especially as it pertains to cardiac delivery. Even though the risk of serious complications is relatively low (11), repeated deliveries have not been studied in clinical trials and will remain a limitation of this technique. A noninvasive strategy for gene delivery by the ultrasonic destruction of plasmid-bearing microbubbles has been developed that results in targeted transfection and therapeutic effects in many tissues, including skeletal and cardiac muscle, without delivery to remote nontargeted organs. If effective and safe, such a strategy could become the technique of choice for repeated gene deliveries to any organ accessible to ultrasound. Only a few studies have compared the efficacy of UM gene delivery to standard direct IM injection. Christiansen et al. (7) compared the efficacy of ultrasonic destruction of intravenous or intra-arterial injections of luciferase-reporter plasmid DNA-bound microbubbles to direct IM injections into normal skeletal muscle. Whereas luciferase activity was similar between animals treated with IM and intra-arterial microbubble delivery, they found 100-fold greater luciferase activity in skeletal muscle with IM delivery, as compared with intravenous UM delivery. Similarly Pislaru et al. (13) demonstrated similar luciferase activity in rat skeletal muscle treated with IM plasmid compared with intra-arterial UM delivery; however, they did not assess intravenous UM delivery.
Our study is the first to directly compare IM delivery to UM destruction of plasmid DNA-bearing microbubbles, using a "functional" gene, namely VEGF 165 . At first glance, it does not seem a fair comparison, with transfection efficiency by real-time polymerase chain reaction demonstrating an 8-to 10-fold greater messenger RNA expression for IM delivery as compared with intravenous UM delivery. The magnitude of the difference is similar to that published with reporter genes. This is not surprising given the large discrepancy in total DNA dose delivered, with nearly 100% delivered for IM injection compared with a much lesser fraction for UM delivery. Ultrasound-mediated delivery is a method of targeted intravascular gene delivery that is reliant entirely on local tissue perfusion, whereby transfection is targeted to the vascular endothelium and adjacent perivascular tissues by external ultrasound application. Whereas 100% of the DNA is administered intravenously, due to low blood flow in noncontracting skeletal muscle coupled with marked flow reduction due to iliac artery ligation, only a small fraction, ϳ10%, will enter the ischemic hind limb where it can be delivered. To maximize delivery, we used longer pulsing intervals to allow microbubble replenishment into tissue between destructive ultrasound pulses, a high acoustic power and low frequency (14) , and prolonged the ultrasound delivery time. Using a continuous infusion of DNA-bearing microbubbles, a steady local concentration within the vascular bed is maintained, and repeated application of intermittent high-power ultrasound during the infusion allows for continuous gene delivery as the microbubbles recirculate through the systemic circulation. By scanning along the length of the hind-limb adductor muscles, we were able to deliver plasmid DNA to the entire proximal ischemic bed, resulting in a wider field of delivery. Finally, by continuing ultrasonic destruction for 10 min after completion of microbubble-DNA infusion, we allowed additional delivery of any remaining circulating DNAbearing microbubbles that had not been delivered. Localization of gene transfection: importance for angiogenesis. Despite substantially lower transgene expression, UM delivery resulted in a similar angiogenic effect, by both CEU perfusion imaging and by fluorescent microangiography. Changes in microvascular blood volume were noted earlier with IM gene therapy, suggesting a more rapid onset of angiogenesis in keeping with substantially greater VEGF transgene expression. However, although maximal changes in vessel density by FMA and MBV by CEU were similar in both IM-and UM-treated ischemic muscle, the increase in MBF, arguably a more functional end point, was greater for UM gene therapy. The discordance between marked increases in MBV and more modest changes in MBF in IM-treated ischemic muscle bears similarity to the neovasculature within highly vascularized tumors, whereby CEU blood volume is greater than surrounding normal tissue; however, due to immature and tortuous vessels, blood velocity is low leading to proportionately lower MBF (15, 16) . This novel observation suggests that UM delivery may have a greater "biologic" response than IM delivery, resulting in a more functional neovasculature despite lower transfection rates. The use of a bicistronic vector encoding for VEGF 165 and a marker gene, enhanced GFP, allowed us to compare the localization of gene transfection by both UM and IM delivery. Ultrasound-mediated gene therapy produced a more diffuse pattern of transfection and was localized to the vascular endothelium of medium to small arterioles and capillaries, with adjacent myocyte transfection D A E B F C Figure 5 Immunofluorescent Staining of IM-and UM-Treated Ischemic Muscle
Examples of immunofluorescent staining of IM-treated (A to C) and UM-treated (D to F) ischemic muscle, at day 17 after ligation. Red ϭ CD31 staining; blue ϭ nuclear staining (TO-PRO-3); yellow ϭ colocalization of GFP and red CD31 staining. Within IM-treated muscle, there were areas without discernable GFP signal (A, yellow arrows), interspersed with regions of strong GFP signal localized predominantly within myocytes (B, white arrows) and surrounding capillaries, with little GFP signal within arterioles (C, red arrows). In comparison, within UM-treated muscle, a more diffuse GFP signal was seen, localized to the vascular endothelium of both capillaries (D, yellow arrows), their surrounding myocytes (E, white arrows), and within small-to medium-sized arterioles (F, red arrows). Scale bar ϭ 50 m. Abbreviations as in Figure 1 .
likely via the surrounding microvasculature. In contrast, IM delivery resulted in more focal pockets of transfection, interspersed with areas of no transfection. Areas of highest transfection were localized to IM injection sites, with a decreasing gradient of transfection with distance from the needle track. The GFP/VEGF transfection was localized predominantly to myocytes, along with adjacent capillaries, with minimal to no arteriolar transfection. The latter finding is in keeping with data from Gal et al. (17) , who used in situ hybridization to show that myocytes represented the site of luciferase expression after IM injections of firefly luciferase-reporter gene into skeletal muscle in rabbits. Thus, our study demonstrates that a strategy of intravascular gene therapy that enhances transfection to the vascular endothelium of arterioles and capillaries in a wider, more diffuse pattern is more effective than one that predominantly targets myocytes, along with adjacent capillaries, in a more focal distribution. Study limitations. For controls, we only studied animals that received no treatment. Ideally, controls should also include groups with: 1) ultrasound alone at the same dosimetry; 2) microbubbles bearing VEGF 165 plasmid DNA alone; and 3) ultrasound and microbubbles bearing control plasmid DNA. We have previously demonstrated that UM delivery of microbubbles bearing GFP plasmid DNA as a microbubble-control plasmid DNA treated group yielded no significant improvement in MBF over time and was similar to control animals that received no treatment (9) .
Conclusions
In summary, despite lower transgene expression, UM microbubble destruction of VEGF 165 may be more effective than direct IM delivery. Ultrasound-mediated delivery results in directed vascular transfection over a wider distribution as compared with IM delivery, which predominantly transfects myocytes and surrounding capillaries. This difference in the localization of gene transfection likely accounts for the more efficient angiogenesis seen with UM delivery of DNA-bearing microbubbles and highlights the importance of the site of transfection in optimizing gene delivery strategies for therapeutic angiogenesis. 
